Somaform's New Interface Line Draws Regulator Eyes

Regulators opened a formal safety review this week of Somaform Augmetics' latest neural-interface line, and with it the oldest question of the enhancement age reopened on schedule: how much is too much, and who decides. The review — routine on paper, prompted by a cluster of adverse reports the company calls statistically ordinary — turns on the newest generation of the deep-integration implants, which sit closer to the seat of cognition than any consumer device before them. No finding has been made; the line remains on the market; Somaform's founder Julian Morrow insists the reports fall well within expected tolerances and that "every meaningful technology is reviewed, and the meaningful ones survive it." His critics counter that the closer an implant sits to the mind, the smaller the margin the public should accept, and that a review is precisely the moment to ask whether the pace of integration has outrun the pace of proof. The augmented are still barely one in twenty humans, and most will never take an implant this deep. But the review is a reminder that with augmentation the frontier is not somewhere out there — it is a few millimeters inside a living skull, and it moves every year.